

New Impact Venture Firm, Cancer Fund, Launches with Investment in Reglagene
Cancer Fund Invests in firm developing affordable and noninvasive therapies that reprogram genes exploited by cancer

PHOENIX, AZ, February 3, 2021 – Marking [World Cancer Day](#), venture firm [Cancer Fund](#) has made its first investment in [Reglagene](#), which is working on an innovative approach to cancer therapies.

Cancer Fund’s mission is to address the breakdown that occurs when promising research gets stuck in the lab and does not reach patients. The investment in Reglagene is the firm’s first investment of many planned out of Cancer Fund I, their first fund.

Cancer Fund is working to turn decades and billions of dollars of cancer research into innovative solutions that help cancer patients. It is led by Managing Director Anthony Bajoras, supported by a talented national team of advisors, and powered by a diverse and growing community of individual investors seeking a more direct way to improve options and outcomes for cancer patients whom Bajoras describes as “more Main Street than Wall Street”.

“Few, if any, would describe themselves as investors but many have historically supported the mission by donating to cancer charities. These are ordinary people helping do something extraordinary. Too many important cancer innovations never make it out of the lab because they lack the funding needed for testing, approval, production, and launch,” Bajoras said. “Cancer Fund is committed to delivering more than hope by helping to get powerful innovation to the patients who need them.”

“This investment marks an important milestone, not only for our investors, for Reglagene, and for cancer patients today, but for all of the people we care about that will be diagnosed in the future. Because, when that moment comes, we’ll wish we would have done more,” said Bajoras.

Reglagene, one of the most exciting startups in the cancer innovation space, recently closed their Seed round of funding and will use this investment to move through the preclinical stage and eventually to clinical human trials.

“Reglagene is thrilled to become a portfolio company of the Cancer Fund,” Reglagene CEO Richard Austin said. “Receiving funding during a biotechnology company’s seed stage is extremely impactful by moving medicines from the lab bench to the clinic. We’ve learned a lot from Anthony and his colleagues at Cancer Fund. We aim to build on this relationship as we develop new medicines that treat therapy-resistant cancers.”

Cancer Fund is an impact-focused venture capital firm. It develops and manages venture funds focused on early-stage cancer-related companies to help them move innovations from the lab to patients. Their first fund, Cancer Fund I, LLC, is currently accepting new investors to help fund a portfolio of investments in companies developing cancer innovations.

Media Contact

Brad Dugard
S+C Communications
1.647.268.4599

brad@sandcpr.com
www.sandcpr.com

About Cancer Fund

Cancer Fund's goals in the fight against cancer are simple: Improve patient outcomes. Increase access to care. Reduce costs. Cancer Fund invests in early-stage companies that share those goals and focus on three areas of focus: therapies and management; diagnostics and monitoring; and preventions and enabling technology.

We are driven by our passion to change the future of cancer, now. We understand the complex and often uphill path from startup to growth stage and work closely with founders to build companies for the future.

About Reglagene

Reglagene's mission is to discover and develop low-cost and noninvasive therapeutic solutions that regain control of genes exploited by cancer to keep patients responsive to treatment. Reglagene's technology is the product of 20 years of meticulous research from the labs of Professor Laurence Hurley at the University of Arizona. Professor Hurley discovered that unusual DNA structures called "quadruplexes," found in many genes exploited by cancer and other diseases, are actually master controllers of gene expression.

Disclaimer

Contents of this release are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of Cancer Fund or its affiliates in any jurisdiction. Cancer Fund does not intend to solicit and IS not soliciting, any action with respect to any Security or any other contractual relationship. Nothing in this release or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful.

Forward Looking Statements

When used herein, the words "anticipate", "believe", "could", "estimate", "expect", "going forward", "intend", "may", "ought to", "plan", "project", "seek", "should", "will", "would" and similar expressions, as they relate to Cancer Fund, Cancer Fund affiliates including Cancer Fund I, Cancer Fund's management, or any of their actual or prospective investments, are intended to identify forward-looking statements. These forward-looking statements reflect Cancer Fund's views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known,-unknown, and unknowable risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of-Cancer Fund's or its affiliates business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, various business opportunities that Cancer Fund may or may not pursue, changes in population growth and other demographic trends, including mortality, morbidity and longevity rates, persistency levels,-Cancer Fund's ability to identify, measure, monitor and control risks in Cancer Fund's business, including its ability to manage and adapt its overall risk profile and risk management practices, and seasonal fluctuations and factors beyond Cancer Fund's control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Cancer Fund undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.